Key Developments: Mitsubishi Tanabe Pharma Corp (MTZXF.PK)
12.77USD
31 May 2013
$0.31 (+2.49%)
$12.46
$12.77
$12.77
$12.77
200
38
$15.63
$12.46
Latest Key Developments (Source: Significant Developments)
R&I Affirms Mitsubishi Tanabe Pharma Corp's Rating at "A+"; Rating Outlook Stable
Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Mitsubishi Tanabe Pharma Corp at "A+". The rating outlook is stable. Full Article
NIPRO CORP to Sell Shares of Bipha Corporation to Mitsubishi Tanabe Pharma Corporation
NIPRO CORP announced that it has decided to sell 20,580 shares of Bipha Corporation to Mitsubishi Tanabe Pharma Corporation, effective September 5, 2012. As a result, Mitsubishi Tanabe Pharma Corporation will hold a 100% stake in Bipha Corporation, up from 51%, while NIPRO CORP will hold no stake in Bipha Corporation, down from 49%. Full Article
AnGes MG, Inc. Signs Exclusive Distribution Right License Agreement with Mitsubishi Tanabe Pharma Corporation
AnGes MG, Inc. announced that it and Mitsubishi Tanabe Pharma Corporation have signed an exclusive distribution right license agreement, of a gene therapy drug of the Company. Full Article
Synageva BioPharma Corp And Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration With Second Program
Synageva BioPharma Corp and Mitsubishi Tanabe Pharma Corporation announced to develop a second protein therapeutic for an undisclosed orphan disease using Synageva’s product development capabilities and protein expression platform. Under the terms of the agreement, Mitsubishi Tanabe Pharma will make an upfront payment of $9 million. Synageva will receive reimbursement for development costs, potential future development and commercial payments, as well as royalties from potential product revenue. Full Article
Medicago Inc And Mitsubishi Tanabe Pharma Corporation Announces Pharma Corporation Strategic Alliance
Medicago Inc announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement on March 6, 2012. The objectives of the March 2012 strategic alliance with MTPC are to develop and commercialize at least three new vacciSnes. MTPC will provide funding for all research and development costs. In exchange for granting licensing rights, Medicago is entitled to receive upfront and payments as well as royalties for each product to be developed under this master agreement. Under this agreement to develop a Rotavirus Like Particle (RLP) vaccine target, MTPC will have the option to license the RLP vaccine target and assume global development, regulatory and commercialization responsibilities, while Medicago is eligible to receive up to a total of CAD33 million in upfront and payments as well as royalties on future sales of the RLP product. Medicago will receive an upfront payment of CAD3 million to begin the initial research on rotavirus. Additional targets under this master agreement are to be selected by Medicago and MTPC at a later date. Full Article
Medicago Inc and Mitsubishi Tanabe Pharma Corporation Enter Into Strategic Alliance To Develop New Vaccines
Medicago Inc announced that it has established a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement. The objectives are to develop and commercialize at least three new vaccines with MTPC who will provide funding for all research and development costs. In exchange for granting licensing rights, Medicago will be entitled to receive upfront and milestone payments as well as royalties for each product to be developed under this master agreement. Under this first agreement to develop a Rotavirus Like Particle (RLP) vaccine target, MTPC will have the option to license the RLP vaccine target and assume global development, regulatory and commercialization responsibilities while Medicago will be eligible to receive up to a total of C$33 million in upfront and milestone payments as well as royalties on future sales of the RLP product. Medicago will receive an upfront payment of C$3 million to begin the initial research on rotavirus. Work on an RLP vaccine target will begin immediately, and additional targets under this master agreement are to be selected by the parties at a later date Full Article
R&I Affirms Mitsubishi Tanabe Pharma Corporation's Rating at "A+"; Rating Outlook Stable
Rating and Investment Information, Inc. (R&I) announced that it has affirmed the rating on Mitsubishi Tanabe Pharma Corporation at "A+". The rating outlook is stable. Full Article
Mitsubishi Tanabe Pharma Corporation Announces Midterm Dividend Payment and Raises Year-end Dividend Outlook for FY Ending March 2012
Mitsubishi Tanabe Pharma Corporation announced that it will issue its midterm dividend of JPY 15.00 per share, or JPY 8,416 million in total, effective December 1, 2011, up from a forecast of JPY 14.00 per share announced on May 10, 2011, from retained earnings to shareholders as of September 30, 2011. The Company also raised its year-end dividend outlook from JPY 14.00 per share to JPY 15.00 per share, for the fiscal year ending March 2012. Full Article
Mitsubishi Tanabe Pharma Corporation Signs Exclusive Development and Sales Contract with Toray Industries, Inc.-Nikkanyakugyo
Nikkanyakugyo reported that Mitsubishi Tanabe Pharma Corporation has signed an exclusive development and sales contract with Toray Industries, Inc., regarding the exclusive development and sales of TRK-820, a new pruritus treatment, in the United States, Canada, Mexico. Full Article
H Lundbeck A/S Partners Mochida Pharmaceutical Co Ltd and Mitsubishi Tanabe Pharma Corp Launch Lexapro 10mg in Japan
H Lundbeck A/S announced that the Company's partners Mochida Pharmaceutical Co., Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (MTPC) have launched Lexapro 10mg (escitalopram) in Japan, for which Mochida obtained the marketing approval following the NHI (National Health Insurance) Drug Price listing. Lexapro is a drug for the treatment of depression and depressive symptoms. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
